• Issue

    Journal of Viral Hepatitis: Volume 16, Issue 8

    529-604
    August 2009
Previous Issue|Next Issue
Export Citation(s)Download PDF(s)

REVIEW ARTICLE

Implication of normal liver enzymes in liver disease

Vincenza Calvaruso,  Antonio Craxì, 
  • Pages: 529-536
  • First Published: 29 July 2009

ORIGINAL ARTICLES

The correlation of hepatocyte nuclear factor 4 alpha and 3 beta with hepatitis B virus replication in the liver of chronic hepatitis B patients

Y. Long,  E. Chen,  C. Liu,  F. Huang,  T. Zhou,  F. He,  L. Liu,  F. Liu,  H. Tang, 
  • Pages: 537-546
  • First Published: 29 July 2009

Chronic hepatitis C and persistent occult hepatitis C virus infection are characterized by distinct immune cell cytokine expression profiles

T. N. Q. Pham,  S. E. Mercer,  T. I. Michalak, 
  • Pages: 547-556
  • First Published: 29 July 2009

Treatment of hepatitis C infection for current or former substance abusers in a community setting

A. John-Baptiste,  M. Varenbut,  M. Lingley,  T. Nedd-Roderique,  D. Teplin,  G. Tomlinson,  J. Daiter,  M. Krahn, 
  • Pages: 557-567
  • First Published: 29 July 2009
Open Access

Never injected, but hepatitis C virus-infected: a study among self-declared never-injecting drug users from the Amsterdam Cohort Studies

C. H. S. B. Van Den Berg,  T. J. W. Van De Laar,  A. Kok,  F. R. Zuure,  R. A. Coutinho,  M. Prins, 
  • Pages: 568-577
  • First Published: 29 July 2009

Pegylated interferon alpha-2b (Peg-IFN α-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN α-2b plus ribavirin

T. Oze,  N. Hiramatsu,  T. Yakushijin,  M. Kurokawa,  T. Igura,  K. Mochizuki,  K. Imanaka,  A. Yamada,  M. Oshita,  H. Hagiwara,  E. Mita,  T. Ito,  Y. Inui,  T. Hijioka,  S. Tamura,  H. Yoshihara,  E. Hayashi,  A. Inoue,  Y. Imai,  M. Kato,  Y. Yoshida,  T. Tatsumi,  K. Ohkawa,  S. Kiso,  T. Kanto,  A. Kasahara,  T. Takehara,  N. Hayashi, 
  • Pages: 578-585
  • First Published: 29 July 2009

Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin

N. Hiramatsu,  T. Oze,  T. Yakushijin,  Y. Inoue,  T. Igura,  K. Mochizuki,  K. Imanaka,  A. Kaneko,  M. Oshita,  H. Hagiwara,  E. Mita,  T. Nagase,  T. Ito,  Y. Inui,  T. Hijioka,  K. Katayama,  S. Tamura,  H. Yoshihara,  Y. Imai,  M. Kato,  Y. Yoshida,  T. Tatsumi,  K. Ohkawa,  S. Kiso,  T. Kanto,  A. Kasahara,  T. Takehara,  N. Hayashi, 
  • Pages: 586-594
  • First Published: 29 July 2009

Evidence for action of ribavirin through the hepatitis C virus RNA polymerase

N. A. Cannon,  M. J. Donlin,  L. M. Mayes,  A. C. Lyra,  A. M. Di Bisceglie,  J. E. Tavis, 
  • Pages: 595-604
  • First Published: 29 July 2009